UNI-EN 28:Preliminary consolidated financial statements for the period January 1 to 31 December 2012.
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 28 | / | 2013 | | ||||||
Date of issue: | 2013-03-01 | ||||||||||
Short name of the issuer | |||||||||||
SOPHARMA AD | |||||||||||
Subject | |||||||||||
Preliminary consolidated financial statements for the period January 1 to 31 December 2012. | |||||||||||
Official market - legal basis | |||||||||||
Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne | |||||||||||
Unofficial market - legal basis | |||||||||||
Contents of the report: | |||||||||||
Preliminary consolidated financial statements for the period January 1 to 31 December 2012. 1. Financial statements 2. Notes to the financial statements 3. Mangement report | |||||||||||
Annexes | |||||||||||
File | Description | ||||||||||
2012 Q4 preliminary consolidated FS.zip 2012 Q4 preliminary consolidated FS.zip | Preliminary consolidated financial statements for the period January 1 to 31 December 2012. |
SOPHARMA AD | |||||||||||||
(fullname of the issuer) | |||||||||||||
SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
(short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
1220 | Sofia | ||||||||||||
(post code) | (city) | ||||||||||||
IlienskoShosse | 16 | ||||||||||||
(street) | (number) | ||||||||||||
+359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
(phone number) | (fax) | ||||||||||||
(e-mail) | (web site) | ||||||||||||
nd | |||||||||||||
(NIP) | (REGON) |
SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
Date | Name | Position / Function | Signature | ||
2013-03-01 | Ognian Donev | Executive Director |
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to None PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.